Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the sale, the insider directly owned 1,308,103 shares in the company, valued at $9,719,205.29. This trade represents a 1.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Beth Hecht also recently made the following trade(s):

• On Monday, December 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.01, for a total value of $116,835.67.
• On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total transaction of $123,335.80.

Xeris Biopharma Trading Down 3.5%

Shares of NASDAQ XERS traded down $0.26 during midday trading on Monday, hitting $7.09. The company’s stock had a trading volume of 3,747,880 shares, compared to its average volume of 3,273,940. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -70.89 and a beta of 0.50. The stock has a fifty day moving average price of $7.57 and a 200 day moving average price of $7.10. Xeris Biopharma Holdings, Inc. has a one year low of $3.14 and a one year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XERS has been the topic of a number of recent analyst reports. Piper Sandler increased their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Oppenheimer reiterated an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Zacks Research cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Friday, November 7th. Finally, Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.50.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in XERS. Calamos Advisors LLC bought a new stake in Xeris Biopharma in the third quarter valued at approximately $1,116,000. AQR Capital Management LLC grew its holdings in Xeris Biopharma by 13.4% in the 1st quarter. AQR Capital Management LLC now owns 946,766 shares of the company’s stock worth $5,198,000 after acquiring an additional 111,826 shares during the last quarter. Voya Investment Management LLC grew its holdings in Xeris Biopharma by 866.6% in the 3rd quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock worth $3,257,000 after acquiring an additional 358,689 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Xeris Biopharma by 1,679.1% in the second quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock valued at $1,329,000 after acquiring an additional 268,572 shares during the period. Finally, Savvy Advisors Inc. bought a new position in shares of Xeris Biopharma during the second quarter valued at about $189,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.